October 31, 2022
Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…
September 21, 2022
September 21, 2022
September 21, 2022
September 21, 2022
September 21, 2022
September 21, 2022
July 8, 2022
March 29, 2022
March 29, 2022
March 29, 2022
March 29, 2022